NeuroVasx, Inc. Announces Launch of NeuroEdge(TM) Neurovascular Catheter

Apr 16, 2001, 01:00 ET from NeuroVasx, Inc.

    PLYMOUTH, Minn., April 16 /PRNewswire/ -- NeuroVasx, Inc. today announced
 that it has launched its NeuroEdge(TM) catheter, the latest in a line of
 microcatheters designed specifically for diagnosis and treatment of
 cerebrovascular disorders including stroke.  "The NeuroEdge(TM) catheter
 leverages the same advanced technology as the Sub-MicroInfusion Catheter
 launched last year," said Jeffrey A. Lee, NeuroVasx President and CEO.  "The
 extremely low profile of the NeuroEdge(TM) catheter is a distinct advantage in
 the precise delivery of materials far distal in the neurovasculature where
 very small, tortuous vessels are present," said Lee.
     NeuroVasx, Inc. is a development stage company founded in 1997 focused on
 developing and marketing a portfolio of unique catheter and implant
 technologies to treat acute stroke, aneurysms and other cerebrovascular
 disorders.  Stroke is the third leading cause of death and is the leading
 cause of adult disability in the United States.  The potential future U.S.
 market for stroke management devices is estimated to be $2 billion.
 
 

SOURCE NeuroVasx, Inc.
    PLYMOUTH, Minn., April 16 /PRNewswire/ -- NeuroVasx, Inc. today announced
 that it has launched its NeuroEdge(TM) catheter, the latest in a line of
 microcatheters designed specifically for diagnosis and treatment of
 cerebrovascular disorders including stroke.  "The NeuroEdge(TM) catheter
 leverages the same advanced technology as the Sub-MicroInfusion Catheter
 launched last year," said Jeffrey A. Lee, NeuroVasx President and CEO.  "The
 extremely low profile of the NeuroEdge(TM) catheter is a distinct advantage in
 the precise delivery of materials far distal in the neurovasculature where
 very small, tortuous vessels are present," said Lee.
     NeuroVasx, Inc. is a development stage company founded in 1997 focused on
 developing and marketing a portfolio of unique catheter and implant
 technologies to treat acute stroke, aneurysms and other cerebrovascular
 disorders.  Stroke is the third leading cause of death and is the leading
 cause of adult disability in the United States.  The potential future U.S.
 market for stroke management devices is estimated to be $2 billion.
 
 SOURCE  NeuroVasx, Inc.